As drugs like Ozempic, Rybelsus, and Wegovy gain attention for treating diabetes and supporting weight loss, researchers are exploring how they might affect other conditions, including liver disease. In this faculty Q&A, Michigan Medicine hepatologist Robert Fontana, M.D., discusses the growing interest in GLP-1 drugs and what doctors are watching for as research continues.